巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Kintara Therapeutics

    KTRA
    0.149
    0.000
    2.94%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Kintara Therapeutics - 延遲價格・最後更新於 23/05 3:04
    最高位
    0.150
    最低位
    0.149
    開市價
    --
    前收市價
    0.153
    成交量(千)
    5.00
    成交額(百萬)
    0.00
    買入
    0.149
    賣出
    0.150
    每手股數
    --
    市值(百萬)
    9.73
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    2.850 - 0.141
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Kintara Therapeutics
    證券代碼
    KTRA.US
    所屬板塊
    Biotechnology
    公司業務
    Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications.
    發行量
    43174989
    公司總部
    12707 High Bluff Drive, Suite 200
    公司網址
    https://www.kintara.com
    公司電郵
    ir@delmarpharma.com
    公司電話
    +1 858 350-4364
    暫無內容

    關於

    Kintara Therapeutics(KTRA.US)所屬的行業板塊為Biotechnology。
    Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications.
    詳細公司背景可參考: https://www.kintara.com